Verisante Announces New Clinical Trials, Collaborations for Core Cancer Detection Technology | GenomeWeb

Verisante Technology this week announced several milestones in the development of its Raman spectroscopy-based cancer detection technology.

The company said that it has completed a clinical trial investigating the use of its Verisante Core device for the detection of lung cancer; launched a clinical study on use the Core for the detection of colon cancer; and entered a collaboration with the British Columbia Cancer Agency and China's Fujian Normal University to develop the Core device for detection of nasopharyngeal cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.